BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21826607)

  • 21. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
    Smalley KS; Nathanson KL; Flaherty KT
    Cancer Res; 2009 Apr; 69(8):3241-4. PubMed ID: 19351826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting patients for KIT inhibition in melanoma.
    Carvajal RD; Hamid O; Antonescu CR
    Methods Mol Biol; 2014; 1102():137-62. PubMed ID: 24258978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oncogen dependent regulation of the migration and proliferation of human tumor cells].
    Garay TM
    Magy Onkol; 2016 Nov; 60(4):339-342. PubMed ID: 27898753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences.
    Hanrahan AJ; Solit DB
    Cancer Res; 2022 Jan; 82(1):12-14. PubMed ID: 34983783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Taking the stress out of melanoma.
    Martin MJ; Carling D; Marais R
    Cancer Cell; 2009 Mar; 15(3):163-4. PubMed ID: 19249673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A complex but promising therapy.
    Ronai Z
    Pigment Cell Melanoma Res; 2010 Apr; 23(2):151-2. PubMed ID: 20394679
    [No Abstract]   [Full Text] [Related]  

  • 29. Kinase regulation by hydrophobic spine assembly in cancer.
    Hu J; Ahuja LG; Meharena HS; Kannan N; Kornev AP; Taylor SS; Shaw AS
    Mol Cell Biol; 2015 Jan; 35(1):264-76. PubMed ID: 25348715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular profiling of melanoma and the evolution of patient-specific therapy.
    Gajewski TF
    Semin Oncol; 2011 Apr; 38(2):236-42. PubMed ID: 21421113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy.
    Carlomagno F; Chiariello M
    J Mol Med (Berl); 2014 Jul; 92(7):723-33. PubMed ID: 24906458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer: Melanoma troops massed.
    Huang PH; Marais R
    Nature; 2009 May; 459(7245):336-7. PubMed ID: 19458705
    [No Abstract]   [Full Text] [Related]  

  • 33. Analysis of the genome to personalize therapy for melanoma.
    Davies MA; Samuels Y
    Oncogene; 2010 Oct; 29(41):5545-55. PubMed ID: 20697348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapies in gynecologic cancers and melanoma.
    Ortega E; Marti RM; Yeramian A; Sorolla A; Dolcet X; Llobet D; Abal L; Santacana M; Pallares J; Llombart-Cussac A; Matias-Guiu X
    Semin Diagn Pathol; 2008 Nov; 25(4):262-73. PubMed ID: 19013892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare victory in fight against melanoma.
    Ledford H
    Nature; 2010 Sep; 467(7312):140-1. PubMed ID: 20829766
    [No Abstract]   [Full Text] [Related]  

  • 36. Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance.
    Philip M; Schietinger A
    Trends Immunol; 2015 Nov; 36(11):665-667. PubMed ID: 26440701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-Derived In Vitro and In Vivo Models of Cancer.
    Claridge SE; Cavallo JA; Hopkins BD
    Adv Exp Med Biol; 2022; 1361():215-233. PubMed ID: 35230691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hope in translation.
    Nature; 2010 Sep; 467(7315):499. PubMed ID: 20881968
    [No Abstract]   [Full Text] [Related]  

  • 39. Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al.
    Anforth R; Fernandez-Penas P
    Acta Derm Venereol; 2017 Nov; 97(10):1267-1268. PubMed ID: 28795761
    [No Abstract]   [Full Text] [Related]  

  • 40. Ctr1-ing BRAF signaling with copper.
    Jarrett SG; D'Orazio JA
    Pigment Cell Melanoma Res; 2014 Sep; 27(5):689-91. PubMed ID: 24835481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.